T0	Participants 54 119	patients with hormone receptor-positive metastatic breast cancer:
T1	Participants 436 641	Patients with newly metastatic disease or recurred after adjuvant tamoxifen (stratum 1), or recurred during/after adjuvant aromatase inhibitor (AI) or after failed first-line AI (stratum 2), were eligible.
T2	Participants 1856 1883	subset appropriate patients